P2RY12 and coronary artery disorder: The combination of P2Y12 inhibitors with ASA monotherapy is known tobe a great ally in the management of patients with coronary artery disease(CAD), be it acute or stable, and it reduces the risk of atherothromboticphenomena, as well as stent thrombosis rates following PCI.21-23 This reduced ischemia risk is, however, indisputablyassociated with higher bleeding rates.22-25